Patients with high- or very high-risk prostate cancer undergo variable staging pathways, with university teaching hospitals more likely to offer PSMA PET/CT than other settings (33.3% vs 12.0%, P = .023).<h4>Conclusions</h4>This survey shows the current state of UK prostate MRI practice, including universal pre-biopsy MRI. This evidence concerns the gene FOLH1 and prostate carcinoma.